Amgen, Inc. (NASDAQ:AMGN)

CAPS Rating: 4 out of 5

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Results 1 - 20 of 335 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar afewgoodstocks14 (51.87) Submitted: 5/13/2014 1:33:33 PM : Outperform Start Price: $111.69 AMGN Score: +4.31

Div. (Yield) $2.44 (2.2%)

Recs

0
Member Avatar tbittker (< 20) Submitted: 5/11/2014 11:50:10 AM : Outperform Start Price: $111.17 AMGN Score: +5.53

Extensive patents. Demographics positive. May have a breakthrough drug in lipid control.

Recs

0
Member Avatar pchop123 (79.52) Submitted: 4/26/2014 11:39:15 PM : Outperform Start Price: $111.17 AMGN Score: +4.58

rebound imminent

Recs

0
Member Avatar dswallen (45.41) Submitted: 4/24/2014 1:21:55 PM : Outperform Start Price: $113.54 AMGN Score: +2.88

Dividend growth + several great drugs already on the market + a great pipeline. This is the best name in Biotech.

Recs

0
Member Avatar TerryHoodSr (34.74) Submitted: 4/15/2014 9:52:51 AM : Outperform Start Price: $114.72 AMGN Score: -0.48

trade buy@ 113 TP 129

Recs

0
Member Avatar Dividends500 (68.63) Submitted: 3/26/2014 4:37:49 PM : Outperform Start Price: $119.35 AMGN Score: -7.02

Dividends500 tracks the 200 strongest dividends in the S&P 500. To qualify as a strong dividend, the company must meet two simple requirements:

- A payout ratio below 50%
- An increasing dividend from the prior year

Because there are more than 200 dividend paying companies in the S&P 500 that meet these requirements, the qualifying companies with the largest dividend yields were chosen.

Dividends500 intends to test this FactSet article, which highlights these strong dividend paying companies and their outperformance versus the S&P 500 as a whole (Page 12).

http://www.factset.com/websitefiles/PDFs/dividend/dividend_12.16.13

If you have questions or see something you think is inaccurate feel free to let me know.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 2/25/2014 9:41:55 AM : Outperform Start Price: $119.17 AMGN Score: -3.08

AMGN BP 115 TP 131 REV 1yr 10% EPS 1yr 16%

Recs

0
Member Avatar jcpalmer (< 20) Submitted: 2/13/2014 10:53:03 AM : Outperform Start Price: $122.47 AMGN Score: -8.32

NYT just published an article about Amgen research
on diabetes using grizzly bears while hibernating. This could lead to new and effective treatments for this most important unmet need.

Recs

0
Member Avatar charlie3brown (< 20) Submitted: 2/7/2014 8:02:08 PM : Outperform Start Price: $66.11 AMGN Score: +39.89

This was one of the first stocks I invested in when attending college back in the early 1980s. It helped me pay my rent bill back then. Biotech stocks are very high risk. A novice will probably be safer investing in one of the many index funds now available.

Recs

0
Member Avatar Macabre (42.57) Submitted: 2/6/2014 11:13:22 AM : Outperform Start Price: $115.07 AMGN Score: -5.28

The drugs that made Amgen the giant that it is today are under threat, due to biosimilars entering the market. Normally, that would be a point of concern, driving investors to sell. However, the company has been investing, heavily, in advancing it's pipeline over the last decade. Those investments are coming to fruition, as the company now has a stellar pipeline of new therapeutics in late-stage clinical trials. One drug (evolocumab), in particular, is estimated to outperform the drugs that made Amgen rich. The next 2-3 years will see some declines, but the 5+ year outlook is going to be spectacular.

Recs

0
Member Avatar WHOVPLLC (24.70) Submitted: 12/31/2013 1:05:16 PM : Outperform Start Price: $113.47 AMGN Score: +0.76

Amgen is one of the leading biotechnology large Pharma companies in the United States. In the nineteen-seventies I was a Venture Capital investor in the company when it was small and just emerging. Amgen is a current BUY for 2014 and beyond.

Recs

0
Member Avatar Elmer22003 (35.59) Submitted: 9/13/2013 10:52:56 PM : Outperform Start Price: $114.51 AMGN Score: -8.46

Stock price undervalues pipeline potential.

Recs

0
Member Avatar onthemv (< 20) Submitted: 8/19/2013 3:45:07 PM : Underperform Start Price: $103.00 AMGN Score: +0.78

Hello

Some of patents are going to expire according to Sources.

Regards
Raghu

Recs

1
Member Avatar SoftDad (< 20) Submitted: 6/17/2013 8:20:07 PM : Outperform Start Price: $98.06 AMGN Score: +5.06

Amgen has a great pipeline of lifesaving biologic therapies. It has a proven track record of bringing highly innovative and effective drugs to market.

Recs

1
Member Avatar rossnr3 (67.60) Submitted: 6/7/2013 11:19:18 AM : Outperform Start Price: $97.77 AMGN Score: +5.26

Strong late stage pipeline; strong cash flow; competition will erode advantage over time.

Recs

0
Member Avatar theo20 (< 20) Submitted: 3/28/2013 4:35:07 PM : Outperform Start Price: $100.24 AMGN Score: -3.96

inertia or momentum

Recs

2
Member Avatar bclan13 (99.04) Submitted: 2/5/2013 2:14:55 AM : Underperform Start Price: $83.62 AMGN Score: -15.11

I don't see anything replacing the big supportive care indications, which will probably get cut in half in coming years by a combination of biosimilars and increasing price sensitivity by numerous governments. This said,, it's a hard call for me be ause Amgen all of a sudden appears to have a phenomenal government affairs dept, securing some positive legislation in the most recent fiscal cliff deal

Recs

0
Member Avatar JorgeAura (20.79) Submitted: 2/2/2013 4:54:07 PM : Underperform Start Price: $83.00 AMGN Score: -16.18

Nasdaq in maximums.

Recs

0
Member Avatar jrai (< 20) Submitted: 7/23/2012 12:15:29 PM : Outperform Start Price: $74.01 AMGN Score: +18.54

I have an option which expires middle of 2013.

The exercise rate is $65.

At what price does the board think is the best price over this period to exercise the option?

Thanks for your help

Recs

1
Member Avatar jamescraymond (< 20) Submitted: 5/8/2012 11:16:47 AM : Outperform Start Price: $66.73 AMGN Score: +37.55

Amgen will continue to innovate and perform like a midsize company. There will always be a demand for new bio pharm products.

Featured Broker Partners


Advertisement